Tanespimycin (17-AAG) Liposomes, Formulation XT28.1

Mfr.No.	DLL-0011, DLL-0011-2ML, DLL-0011-10ML
Description	PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
Alternative Names	17-AAG; CP127374; NSC-330507; KOS 953
Average Size	70-120 nm
Hydration Solution	300 mM sucrose
External Solution	XT28.1
Signaling pathway	Heat shock response (HSR) pathway
Concentration	2.5 mg/mL
Concentration Total Lipid	60 mM
Types of Liposomes	Drug Loaded Liposomes
Target	Hsp90

Have you used this product?

Combination SKU	Supplier No.	Volume	Your price	Quantity
BHB19400006-1	DLL-0011-2ML	2mL	$995		Add to Cart
BHB19400006-2	DLL-0011-10ML	10mL	$2995		Add to Cart